Clinical Trials Logo

Sintilimab clinical trials

View clinical trials related to Sintilimab.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04618367 Completed - Clinical trials for Carcinoma, Hepatocellular

HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

This study intends to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus lenvatinib and Sintilimab for patients hepatocellular carcinoma and portal vein tumor thrombus.

NCT ID: NCT04271813 Completed - Colorectal Cancer Clinical Trials

Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)

Start date: June 1, 2020
Phase: Phase 2
Study type: Interventional

This study is designed to evaluate the efficacy and safety of the combination of Anlotinib and Sintilimab in advanced colorectal cancer as first-line treatment.

NCT ID: NCT03936452 Completed - Radiotherapy Clinical Trials

Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma

Start date: April 28, 2019
Phase: Phase 2
Study type: Interventional

This study aims to investigate the treatment of previously untreated stage I-II Extranodal NK/T Cell Lymphoma with sintilimab, peg-aspargase and anlotinib, "sandwich" with radiotherapy. The primary endpoint is the complete response rate (CRR) at the end of the treatment, and the second endpoints are CRR after two cycles of the combined regimen (CRR2), overall response rate (ORR) at the end of the treatment, survival time (OS and PFS) and toxicities.